Home › NDC Lookup › Ingredients › Calcium Acetate › 23155-0621-02
⚪image loading
(from DailyMed)

Calcium Acetate 667 mg Tablet, 200-count — NDC 23155-621-02 (Billing 23155-0621-02)

by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · 200 TABLET in 1 BOTTLE

This is a package of 200 tablets of Calcium Acetate 667 mg Tablet from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., marketed since Jan 2015 and currently FDA-listed; retail pharmacies pay about $0.4387 per tablet (NADAC). It is this product's only package size.

NDC 23155-0621-02
🏷️ FDA NDC (as labeled) 23155-621-02 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 23155-621-02
Product NDC 23155-621
11-digit billing NDC 23155062102
NCPDP billing unit EA — each (per item)
RxCUI 197433
UNII Y882YXF34X
UPC 0323155621020
Application # ANDA202885
SPL Set ID ac4975aa-0ee9-4473-81e2-839f1556e684
Established class (EPC) Blood Coagulation Factor; Cations; Phosphate Binder
Mechanism of action Phosphate Chelating Activity
Physiologic effect Increased Coagulation Factor Activity
Chemical class Calcium; Divalent
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2015-01-22
Route ORAL
Dosage form TABLET
Substance CALCIUM ACETATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 52800020100320
GPI class Calcium Acetate (Phos Binder)
GCN Seq No 027508
GCN 75051
HICL code 004884
Ingredient (HICL) Calcium Acetate
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1A
Therapeutic class — specific (HIC3) Electrolyte Depleters
AHFS code 40:18.19.00
AHFS class Phosphate-Removing Agents
FDB label name CALCIUM ACETATE 667 MG TABLET
FDB brand name Calcium Acetate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 027508
  • GCN: 75051
  • GPI-14 (Medi-Span): 52800020100320
  • HICL (First Databank): 004884
  • AHFS class code: 40:18.19.00
  • RxCUI (RxNorm): 197433
Why two NDCs? The FDA registers this code as 23155-621-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 23155-0621-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Drugs for treatment of hyperkalemia and hyperphosphatemia class.

Drug family (ATC) Drugs for treatment of hyperkalemia and hyperphosphatemia
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CALCIUM ACETATE 667 MG TABLET Ingredient Calcium Acetate
📖 What it is MedlinePlus · NLM

Calcium acetate is used to control high blood levels of phosphorus in people with kidney disease who are on dialysis (medical treatment to clean the blood when the kidneys are not working properly). Calcium acetate is in a class of medications called phosphate binders. It binds phosphorus that you get from foods in your diet and prevents it from being absorbed into your blood stream.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It lowers the phosphorus in your blood if you have end stage renal disease. Failing kidneys can't clear phosphorus well, so it builds up. Calcium acetate helps by binding phosphate...
  • Take it by mouth with each meal. It needs to be in your stomach with your food to bind the phosphate. Your prescriber will adjust how many you take based on your blood tests, so fo...
  • The most common are high blood calcium, nausea and vomiting. Some people also report dizziness, swelling or weakness. Call your doctor if you have ongoing nausea, constipation, poo...
  • Avoid them unless your doctor says otherwise. Calcium supplements and calcium-based antacids add more calcium and raise the risk of high blood calcium. Check with me before taking...
📖 Read our full Calcium Acetate guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.439 $87.74 / 200 tablets
Medicaid paysCMS SDUD · 12 mo $0.4274 $85.48 / 200 tablets
Medicare drug plans payPart D · Q2 2026 $0.4115 $82.30 / 200 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Feb 2026 Apr 2026 Jul 2026 $0.452 $0.418
▲ Up 5% over the last 8 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
23155-0621-02 You're viewing this Main listing 200 TABLET in 1 BOTTLE 2015-01-22 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Calcium Acetate 667 mgthis 23155-0621-02 Heritage 200 tablets $0.439 AB Availability likely —
Calcium Acetate 667 mg 62135-0192-22 Chartwell 200 tablets $0.439 AB Availability likely —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2015
On the market since
Jan 2015
📍
2026
Currently FDA-listed
11 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintEP114
Size13 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 2S7830E561
    Crospovidone is a synthetic polymer derived from povidone. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the active ingredient can be absorbed.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 368GB5141J
    A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Application holderHERITAGE PHARMACEUTICALS INC
FDA applicationANDA202885 (ANDA)
Labeler code23155
First marketedJan 2015
Product typeHuman Prescription Drug
Portfolio253 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients 🔬 Clinical Studies 🧪 Nonclinical Toxicology 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 48 words ▾

1 INDICATIONS & USAGE Calcium acetate tablet is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). Calcium acetate tablet is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. ( 1 )

⏱️ Dosage and Administration 88 words ▾

2 DOSAGE & ADMINISTRATION The recommended initial dose of calcium acetate tablets for the adult dialysis patient is 2 tablets with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3 to 4 tablets with each meal.

Starting dose is 2 tablets with each meal. (2) Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Most patients require 3 to 4 tablets with each meal.

(2)

💊 Dosage Forms and Strengths 20 words ▾

3 DOSAGE FORMS & STRENGTHS Tablet: 667 mg calcium acetate per tablet. Tablets: 667 mg calcium acetate per tablet. (3)

⛔ Contraindications 7 words ▾

4 CONTRAINDICATIONS Patients with hypercalcemia. Hypercalcemia. (4)

⚠️ Warnings and Cautions ~1 min read ▾

5 WARNINGS AND PRECAUTIONS Treat mild hypercalcemia by reducing or interrupting calcium acetate tablet and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate tablets. (5.1) Hypercalcemia may aggravate digitalis toxicity. (5.2)

5.1Hypercalcemia Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with calcium acetate. An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures.

Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage or discontinue the treatment, depending on the severity of hypercalcemia. More severe hypercalcemia (Ca>12 mg/dL) is associated with confusion, delirium, stupor and coma.

Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy.

Decreasing or discontinuing Vitamin D therapy is recommended as well. Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification.

The long term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined. Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg 2 /dL 2 .

5.2Concomitant Use with Medications Hypercalcemia may aggravate digitalis toxicity.

🤒 Adverse Reactions ~2 min read ▾

6 ADVERSE REACTIONS Hypercalcemia is discussed elsewhere [ see Warnings and Precautions (5.1) ]. The most common (>10%) adverse reactions are hypercalcemia, nausea, and vomiting. (6.1). In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy.( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies, calcium acetate has been generally well tolerated. Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients.

Adverse reactions (>2% on treatment) from these trials are presented in Table 1. Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis Preferred Term Total adverse reactions reported for calcium acetate n = 167 n (%) 3 - mo, open-label study of calcium acetate n = 98 n (%) Double-blind, placebo-controlled, cross over study of calcium acetate n = 69 Calcium acetate n (%) Placebo n (%) Nausea 6 (3.6) 6 (6.1) 0 (0.0) 0 (0.0) Vomiting 4 (2.4) 4 (4.1) 0 (0.0) 0 (0.0) Hypercalcemia 21 (12.6) 16 (16.3) 5 (7.2) 0 (0.0) Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting.

More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate-induced hypercalcemia. Isolated cases of pruritus have been reported, which may represent allergic reactions.

6.2Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.

🔄 Drug Interactions 215 words ▾

7 DRUG INTERACTIONS The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl and hydroxyl groups). Calcium Acetate Tablet may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs.

When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.

Calcium acetate tablet may decrease the bioavailability of tetracyclines or fluoroquinolones. (7) When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate tablet, or consider monitoring blood levels of the drug. (7)

7.1Ciprofloxacin In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets approximately 2.7 g, decreased the bioavailability of ciprofloxacin by approximately 50%.

👥 Use in Specific Populations ~1 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1PREGNANCY Pregnancy Category C Calcium acetate tablets contain calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1) ] .

Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.

8.2LABOR & DELIVERY The effects of calcium acetate on labor and delivery are unknown.

8.3NURSING MOTHERS Calcium acetate tablet contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.

8.4PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established.

8.5GERIATRIC USE Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🆘 Overdosage 24 words ▾

10 OVERDOSAGE Administration of calcium acetate tablet in excess of the appropriate daily dosage may result in hypercalcemia [see Warnings and Precautions (5.1) ].

🧬 Clinical Pharmacology 114 words ▾

12 CLINICAL PHARMACOLOGY Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.

12.1MECHANISM OF ACTION Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.

12.2PHARMACODYNAMICS Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

📦 How Supplied / Storage and Handling 88 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Each Calcium Acetate Tablet USP, intended for oral administration, is white, round tablet, Debossed EP 114 on one side and plain on the reverse side. Each calcium acetate tablet contains 667 mg of calcium acetate (anhydrous Ca(CH 3 COO) 2 ; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium and are supplied as follow: Bottles of 200: NDC 23155-621-02 STORAGE: Store at 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

📋 Description 97 words ▾

11 DESCRIPTION Calcium acetate tablet acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C 4 H 6 CaO 4 , and its molecular weight is 158.17.

Its structural formula is: Each calcium acetate tablet contains 667 mg of calcium acetate, (anhydrous; Ca (CH 3 COO) 2 ; MW = 158.17 grams) equal to 169 mg (8.45 mEq) calcium. In addition, each tablet contains following inactive ingredients: crospovidone, magnesium stearate and sodium lauryl sulfate. Calcium acetate tablets are administered orally for the control of hyperphosphatemia in end stage renal failure. structure

💬 Information for Patients 101 words ▾

17 PATIENT COUNSELING INFORMATION Inform patients to take calcium acetate tablets with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety and efficacy to take the drug one hour before or three hours after calcium acetate tablets.

Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000262US04 Revised: 04/2021 logo

🔬 Clinical Studies ~2 min read ▾

14 CLINICAL STUDIES Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid dosage form. Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study. The patients received calcium acetate tablet [667 mg] at each meal for a period of 12 weeks.

The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.

The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented. Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim and Study Completion Time points a Values expressed as mean ± SE. b Ninety-one patients completed at least 6 weeks of the study. c ANOVA of difference in values at pre-study and study completion Parameter Pre-Study Week 4 b Week 8 Week 12 p-value c Phosphorus (mg/dL) a 7.4 ± 0.17 5.9 ± 0.16 5.6 ± 0.17 5.2 ± 0.17

0.01Calcium (mg/dL) a 8.9 ± 0.09 9.5 ± 0.10 9.7 ± 0.10 9.7 ± 0.10

0.01There was a 30% decrease in serum phosphorus levels during the 12 week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.

Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.

The phosphate binding effect of calcium acetate is shown in the Table 3. Table 3: Serum Phosphorus and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm Parameter Pre-Study Post-Treatment p-value b Calcium Acetate Placebo Phosphorus (mg/dL) a 7.3 ± 0.18 5.9 ± 0.24 7.8 ± 0.22 <0.01 Calcium (mg/dL) a 8.9 ± 0.11 9.5 ± 0.13 8.8 ± 0.12 <0.01 a Values expressed as mean ± SE. b ANOVA of calcium acetate vs. placebo after 2 weeks of treatment. Overall, 2 weeks of treatment with calcium acetate statistically significantly (p<0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p<0.01) but clinically unimportant mean of 7%.

🧪 Nonclinical Toxicology 23 words ▾

13 NONCLINICAL TOXICOLOGY

13.1CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.

📄 Package Label / Principal Display Panel 19 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 23155- 621 -02 Calcium Acetate Tablets, USP 667 mg 200 Tablets Rx Only label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
7.8K
Units reimbursed last 4 qtrs
1.4M
Gross reimbursed last 4 qtrs
$606.2K
Avg / prescription
$77.75
Avg / unit
$0.4274
Latest quarter Q4 2025
1.7KRx
Medicaid pays / ea
$0.4274
gross reimbursed
vs
NADAC / ea
$0.4387
acquisition cost
=
Spread
−$0.0113
-3% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
55% FFS 45% MCO
Fee-for-service · 4,250 Rx Managed care · 3,547 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 25,212 units · 323 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 5,786 units · 101 per 100k residents MN Wisconsin: 19,551 units · 331 per 100k residents WI Michigan: 32,858 units · 327 per 100k residents MI New York: 249,212 units · 1,273 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 39,617 units · 936 per 100k residents OR Nevada: 19,344 units · 606 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 3,553 units · 111 per 100k residents IA Illinois: 23,852 units · 190 per 100k residents IL Indiana: 22,374 units · 326 per 100k residents IN Ohio: 92,123 units · 782 per 100k residents OH Pennsylvania: 70,478 units · 544 per 100k residents PA New Jersey: 44,201 units · 476 per 100k residents NJ Massachusetts: 14,940 units · 213 per 100k residents MA California: 482,301 units · 1,238 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 17,044 units · 377 per 100k residents KY West Virginia: no data reported WV Virginia: 12,852 units · 147 per 100k residents VA Maryland: 58,324 units · 944 per 100k residents MD Connecticut: no data reported CT Rhode Island: 7,632 units · 697 per 100k residents RI Arizona: 52,016 units · 700 per 100k residents AZ New Mexico: 25,064 units · 1,186 per 100k residents NM Kansas: 2,225 units · 75.7 per 100k residents KS Arkansas: 4,801 units · 157 per 100k residents AR Tennessee: no data reported TN North Carolina: 25,613 units · 236 per 100k residents NC South Carolina: 8,710 units · 162 per 100k residents SC Delaware: no data reported DE Oklahoma: 8,568 units · 211 per 100k residents OK Louisiana: no data reported LA Mississippi: 3,591 units · 122 per 100k residents MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: 2,490 units · 174 per 100k residents HI Texas: 29,759 units · 97.6 per 100k residents TX Florida: 14,212 units · 62.9 per 100k residents FL
Units reimbursed · per 100k residents
62.91,273
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 1,273 /100k
2 California 1,238 /100k
3 New Mexico 1,186 /100k
4 Maryland 944 /100k
5 Oregon 936 /100k
6 Ohio 782 /100k
7 Arizona 700 /100k
8 Rhode Island 697 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Calcium Acetate — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Calcium Acetate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$337.8K
Claims incl. refills
6K
Beneficiaries
3.8K
Spend / beneficiary
$87.82
Spend / claim
$56.02
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Calcium Acetate — the ingredient across all brands.

Top reported reactions

Renal Failure489
Chronic Kidney Disease467
End Stage Renal Disease437
Acute Kidney Injury380
Diarrhoea335
Nausea270
Fatigue259

Age at onset

Neonate6
Infant2
Child1
Adolescent2
Adult393
Elderly336

Reporter sex

5,422 reports
Male · 48%
Female · 52%
Unknown · 0%

Serious outcomes

Hospitalization2,291
Life-threatening250
Disabling152
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 329 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 23155-0620-41 · Heritage 23155-0649-41 · Heritage →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.